| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Drug Resistance, Bacterial | 16 | 2021 | 1414 | 2.53 | Why? |
| Anti-Bacterial Agents | 31 | 2021 | 10083 | 2.22 | Why? |
| Drug Utilization | 5 | 2019 | 619 | 1.61 | Why? |
| Antimicrobial Stewardship | 6 | 2019 | 931 | 1.47 | Why? |
| Enterobacteriaceae Infections | 7 | 2019 | 529 | 1.47 | Why? |
| Enterobacteriaceae | 6 | 2019 | 395 | 1.22 | Why? |
| beta-Lactamases | 10 | 2019 | 759 | 1.21 | Why? |
| Bacterial Infections | 6 | 2018 | 2229 | 1.09 | Why? |
| Gram-Negative Bacteria | 3 | 2019 | 473 | 1.03 | Why? |
| Drug Resistance, Multiple, Bacterial | 7 | 2019 | 1115 | 1.02 | Why? |
| beta-Lactam Resistance | 3 | 2019 | 150 | 0.99 | Why? |
| Gram-Negative Bacterial Infections | 2 | 2019 | 398 | 0.88 | Why? |
| Bacteria | 4 | 2018 | 1897 | 0.78 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 7 | 2018 | 711 | 0.78 | Why? |
| Dideoxynucleosides | 1 | 2019 | 92 | 0.75 | Why? |
| Glycopeptides | 2 | 2018 | 199 | 0.73 | Why? |
| Raltegravir Potassium | 1 | 2019 | 132 | 0.71 | Why? |
| Lamivudine | 1 | 2019 | 210 | 0.67 | Why? |
| HIV Integrase Inhibitors | 1 | 2019 | 173 | 0.66 | Why? |
| Staphylococcal Infections | 7 | 2018 | 1099 | 0.66 | Why? |
| Skin Diseases, Infectious | 1 | 2018 | 77 | 0.65 | Why? |
| Soft Tissue Infections | 1 | 2018 | 116 | 0.64 | Why? |
| Drug Therapy | 1 | 2019 | 280 | 0.63 | Why? |
| Behavior Therapy | 1 | 2019 | 235 | 0.63 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2018 | 214 | 0.62 | Why? |
| Gram-Positive Bacteria | 1 | 2017 | 230 | 0.61 | Why? |
| Patient Care Bundles | 1 | 2017 | 137 | 0.59 | Why? |
| Vancomycin | 1 | 2018 | 328 | 0.57 | Why? |
| Acinetobacter baumannii | 3 | 2019 | 378 | 0.56 | Why? |
| Drug Prescriptions | 2 | 2019 | 1062 | 0.53 | Why? |
| Cross Infection | 11 | 2020 | 8675 | 0.53 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2017 | 323 | 0.51 | Why? |
| Clostridium Infections | 2 | 2018 | 595 | 0.50 | Why? |
| Europe | 16 | 2019 | 12702 | 0.47 | Why? |
| Escherichia coli | 6 | 2018 | 1547 | 0.44 | Why? |
| Practice Patterns, Physicians' | 3 | 2019 | 4927 | 0.44 | Why? |
| Methicillin Resistance | 2 | 2008 | 77 | 0.41 | Why? |
| Pseudomonas aeruginosa | 3 | 2020 | 652 | 0.39 | Why? |
| Bacteremia | 4 | 2018 | 1372 | 0.39 | Why? |
| Evidence-Based Medicine | 3 | 2018 | 3228 | 0.36 | Why? |
| Microbiota | 2 | 2018 | 1240 | 0.34 | Why? |
| HIV-1 | 2 | 2019 | 3365 | 0.33 | Why? |
| Sepsis | 4 | 2018 | 3517 | 0.32 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2017 | 1475 | 0.31 | Why? |
| Vancomycin-Resistant Enterococci | 2 | 2017 | 104 | 0.31 | Why? |
| Anti-HIV Agents | 1 | 2019 | 2209 | 0.31 | Why? |
| Bacterial Proteins | 4 | 2018 | 1318 | 0.30 | Why? |
| beta-Lactams | 4 | 2018 | 210 | 0.29 | Why? |
| Acinetobacter Infections | 1 | 2008 | 273 | 0.29 | Why? |
| Klebsiella pneumoniae | 4 | 2018 | 658 | 0.28 | Why? |
| Escherichia coli Infections | 2 | 2018 | 348 | 0.27 | Why? |
| Physicians | 2 | 2019 | 4214 | 0.24 | Why? |
| Carbapenems | 4 | 2020 | 343 | 0.24 | Why? |
| Tuberculosis | 1 | 2017 | 2895 | 0.22 | Why? |
| Klebsiella | 2 | 2017 | 35 | 0.22 | Why? |
| Pulmonary Embolism | 1 | 2020 | 4775 | 0.21 | Why? |
| beta-Lactamase Inhibitors | 2 | 2018 | 104 | 0.20 | Why? |
| Biomedical Research | 2 | 2017 | 5270 | 0.20 | Why? |
| Staphylococcus aureus | 1 | 2006 | 844 | 0.20 | Why? |
| Ceftazidime | 2 | 2020 | 134 | 0.19 | Why? |
| Hospitals | 3 | 2017 | 11793 | 0.19 | Why? |
| Humans | 63 | 2021 | 930598 | 0.19 | Why? |
| Disease Outbreaks | 3 | 2018 | 27595 | 0.19 | Why? |
| Drug Combinations | 2 | 2019 | 3852 | 0.19 | Why? |
| Stenotrophomonas maltophilia | 1 | 2019 | 63 | 0.18 | Why? |
| Cephalosporins | 2 | 2018 | 250 | 0.18 | Why? |
| HIV Infections | 5 | 2019 | 11620 | 0.18 | Why? |
| Enterobacter | 1 | 2017 | 18 | 0.18 | Why? |
| Gene Amplification | 1 | 2017 | 85 | 0.17 | Why? |
| Societies, Scientific | 2 | 2018 | 414 | 0.17 | Why? |
| Bile Acids and Salts | 1 | 2018 | 91 | 0.17 | Why? |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2021 | 314 | 0.17 | Why? |
| Interferon beta-1a | 1 | 2020 | 316 | 0.17 | Why? |
| Linezolid | 1 | 2018 | 160 | 0.16 | Why? |
| Epidemics | 1 | 2017 | 6407 | 0.16 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2019 | 952 | 0.16 | Why? |
| Bacterial Load | 1 | 2017 | 179 | 0.16 | Why? |
| Escherichia coli Proteins | 1 | 2017 | 168 | 0.16 | Why? |
| Kidney Function Tests | 1 | 2019 | 520 | 0.16 | Why? |
| Livestock | 1 | 2017 | 184 | 0.16 | Why? |
| Microbial Sensitivity Tests | 4 | 2020 | 2886 | 0.16 | Why? |
| Microbiology | 1 | 2018 | 134 | 0.16 | Why? |
| Americas | 1 | 2017 | 418 | 0.16 | Why? |
| Triglycerides | 1 | 2019 | 478 | 0.15 | Why? |
| Journal Impact Factor | 1 | 2017 | 134 | 0.15 | Why? |
| Klebsiella Infections | 2 | 2018 | 466 | 0.15 | Why? |
| Ciprofloxacin | 1 | 2017 | 130 | 0.15 | Why? |
| Carrier State | 2 | 2018 | 2100 | 0.15 | Why? |
| Quality-Adjusted Life Years | 1 | 2018 | 511 | 0.15 | Why? |
| Ceftriaxone | 1 | 2017 | 365 | 0.15 | Why? |
| Pseudomonas Infections | 1 | 2020 | 425 | 0.15 | Why? |
| Meat | 1 | 2017 | 380 | 0.14 | Why? |
| Cholesterol | 1 | 2019 | 660 | 0.14 | Why? |
| Infection Control | 6 | 2020 | 23131 | 0.14 | Why? |
| Decision Support Techniques | 2 | 2020 | 903 | 0.14 | Why? |
| Infectious Disease Medicine | 1 | 2017 | 311 | 0.13 | Why? |
| Aged | 19 | 2021 | 215776 | 0.13 | Why? |
| International Cooperation | 2 | 2017 | 3436 | 0.13 | Why? |
| Critical Care | 1 | 2017 | 14081 | 0.13 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.13 | Why? |
| Pulmonary Artery | 1 | 2020 | 803 | 0.13 | Why? |
| Specialization | 1 | 2017 | 432 | 0.12 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.12 | Why? |
| Aged, 80 and over | 11 | 2021 | 88759 | 0.12 | Why? |
| Bacterial Typing Techniques | 1 | 2014 | 273 | 0.12 | Why? |
| Hospital Bed Capacity | 1 | 2020 | 1300 | 0.12 | Why? |
| Population Surveillance | 3 | 2017 | 4967 | 0.12 | Why? |
| Liver Function Tests | 1 | 2019 | 1325 | 0.12 | Why? |
| Chlorhexidine | 1 | 2014 | 176 | 0.12 | Why? |
| Communicable Diseases | 2 | 2017 | 2148 | 0.12 | Why? |
| Male | 26 | 2021 | 367725 | 0.11 | Why? |
| Netherlands | 2 | 2018 | 3533 | 0.11 | Why? |
| Female | 26 | 2021 | 380317 | 0.11 | Why? |
| Drug Therapy, Combination | 3 | 2020 | 7268 | 0.11 | Why? |
| Search Engine | 1 | 2018 | 628 | 0.11 | Why? |
| Computed Tomography Angiography | 1 | 2020 | 2153 | 0.10 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.10 | Why? |
| Genotype | 2 | 2018 | 4697 | 0.10 | Why? |
| Blood Platelets | 1 | 2020 | 1704 | 0.10 | Why? |
| Diabetes Complications | 1 | 2021 | 2358 | 0.09 | Why? |
| Cephalosporin Resistance | 2 | 2018 | 12 | 0.09 | Why? |
| Survival Analysis | 2 | 2019 | 7592 | 0.09 | Why? |
| Africa | 1 | 2017 | 2986 | 0.09 | Why? |
| World Health Organization | 2 | 2018 | 4213 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.09 | Why? |
| Membrane Proteins | 1 | 2018 | 1733 | 0.09 | Why? |
| Catheters, Indwelling | 1 | 2008 | 84 | 0.09 | Why? |
| Epidemiological Monitoring | 2 | 2017 | 3493 | 0.08 | Why? |
| Thromboembolism | 1 | 2020 | 2101 | 0.08 | Why? |
| Community-Acquired Infections | 2 | 2017 | 2328 | 0.08 | Why? |
| Anti-Infective Agents, Local | 1 | 2014 | 520 | 0.08 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.08 | Why? |
| Consensus | 2 | 2018 | 6345 | 0.08 | Why? |
| Intensive Care Units | 4 | 2021 | 29594 | 0.08 | Why? |
| Disinfectants | 1 | 2017 | 1077 | 0.08 | Why? |
| Patient Admission | 2 | 2020 | 5250 | 0.08 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2020 | 3388 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.08 | Why? |
| Diarrhea | 1 | 2018 | 2743 | 0.08 | Why? |
| Patient Care | 1 | 2017 | 1664 | 0.08 | Why? |
| Anti-Infective Agents | 1 | 2017 | 1766 | 0.08 | Why? |
| Global Health | 3 | 2018 | 13911 | 0.07 | Why? |
| Retrospective Studies | 12 | 2021 | 105322 | 0.07 | Why? |
| Vitamin D | 1 | 2021 | 2904 | 0.07 | Why? |
| Venous Thrombosis | 1 | 2020 | 2739 | 0.07 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.07 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.07 | Why? |
| Periodicals as Topic | 1 | 2017 | 1492 | 0.07 | Why? |
| Gastrointestinal Microbiome | 1 | 2017 | 1961 | 0.07 | Why? |
| Prevalence | 3 | 2021 | 25773 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.07 | Why? |
| Hospitalization | 6 | 2021 | 54280 | 0.07 | Why? |
| Medical Oncology | 1 | 2020 | 3826 | 0.07 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.06 | Why? |
| Public Health | 3 | 2018 | 16359 | 0.06 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.06 | Why? |
| Hand Hygiene | 1 | 2014 | 1493 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.06 | Why? |
| Guidelines as Topic | 2 | 2020 | 2844 | 0.06 | Why? |
| Italy | 4 | 2021 | 38444 | 0.06 | Why? |
| Adult | 12 | 2021 | 244371 | 0.06 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.06 | Why? |
| Immunocompromised Host | 1 | 2019 | 5150 | 0.06 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.05 | Why? |
| Piperacillin | 1 | 2020 | 63 | 0.05 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.05 | Why? |
| Penicillanic Acid | 1 | 2020 | 58 | 0.05 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.05 | Why? |
| Health Personnel | 3 | 2020 | 29646 | 0.05 | Why? |
| Partial Pressure | 1 | 2021 | 279 | 0.05 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.05 | Why? |
| Leishmaniasis, Visceral | 1 | 2000 | 85 | 0.05 | Why? |
| Alkynes | 1 | 2019 | 98 | 0.05 | Why? |
| Respiratory Tract Infections | 1 | 2020 | 6817 | 0.05 | Why? |
| Risk Factors | 6 | 2020 | 71621 | 0.05 | Why? |
| Kaplan-Meier Estimate | 2 | 2020 | 4260 | 0.05 | Why? |
| Benzoxazines | 1 | 2019 | 103 | 0.05 | Why? |
| Evaluation Studies as Topic | 1 | 2020 | 391 | 0.05 | Why? |
| Intention to Treat Analysis | 1 | 2020 | 673 | 0.05 | Why? |
| Bone Diseases, Infectious | 1 | 1997 | 20 | 0.05 | Why? |
| Hospital Records | 1 | 2018 | 55 | 0.05 | Why? |
| Bile | 1 | 2018 | 56 | 0.05 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2000 | 260 | 0.04 | Why? |
| Nervous System | 1 | 2020 | 303 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2018 | 264 | 0.04 | Why? |
| Tetracycline | 1 | 2017 | 33 | 0.04 | Why? |
| Gene Expression Regulation, Bacterial | 1 | 2017 | 143 | 0.04 | Why? |
| Clinical Medicine | 1 | 2018 | 93 | 0.04 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.04 | Why? |
| Pneumonia, Staphylococcal | 1 | 1996 | 38 | 0.04 | Why? |
| Food Microbiology | 1 | 2017 | 114 | 0.04 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Cyclopropanes | 1 | 2019 | 332 | 0.04 | Why? |
| Bacterial Toxins | 1 | 2018 | 185 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.04 | Why? |
| Minocycline | 1 | 2017 | 101 | 0.04 | Why? |
| Social Media | 1 | 2018 | 5798 | 0.04 | Why? |
| Incidence | 2 | 2017 | 25622 | 0.04 | Why? |
| Myeloid Cells | 1 | 2021 | 808 | 0.04 | Why? |
| Tertiary Care Centers | 3 | 2018 | 8248 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 8811 | 0.04 | Why? |
| Professional Competence | 1 | 2018 | 246 | 0.04 | Why? |
| Fibrinogen | 1 | 2021 | 1048 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| Prognosis | 4 | 2020 | 32490 | 0.04 | Why? |
| Colistin | 1 | 2017 | 217 | 0.03 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.03 | Why? |
| Psychosocial Support Systems | 1 | 2020 | 710 | 0.03 | Why? |
| Return to Work | 1 | 2020 | 579 | 0.03 | Why? |
| Arthritis | 1 | 1997 | 288 | 0.03 | Why? |
| Education | 1 | 2018 | 434 | 0.03 | Why? |
| Fecal Microbiota Transplantation | 1 | 2018 | 372 | 0.03 | Why? |
| Polymerase Chain Reaction | 2 | 2018 | 6740 | 0.03 | Why? |
| Research Support as Topic | 1 | 2017 | 327 | 0.03 | Why? |
| Length of Stay | 2 | 2021 | 11042 | 0.03 | Why? |
| Risk Management | 1 | 2020 | 1044 | 0.03 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1316 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2018 | 1638 | 0.03 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.03 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.03 | Why? |
| Lipids | 1 | 2019 | 1079 | 0.03 | Why? |
| Sweden | 1 | 2019 | 1969 | 0.03 | Why? |
| Flow Cytometry | 1 | 2020 | 2393 | 0.03 | Why? |
| Neoplasms | 1 | 2020 | 17251 | 0.03 | Why? |
| Animals | 2 | 2017 | 78931 | 0.03 | Why? |
| Geography | 1 | 2017 | 1801 | 0.03 | Why? |
| Postoperative Complications | 1 | 2008 | 5861 | 0.02 | Why? |
| Sentinel Surveillance | 1 | 2017 | 1093 | 0.02 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.02 | Why? |
| Monocytes | 1 | 2021 | 2978 | 0.02 | Why? |
| Israel | 1 | 2017 | 2751 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2021 | 4002 | 0.02 | Why? |
| Communicable Disease Control | 1 | 2017 | 29620 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.02 | Why? |
| Dyspnea | 1 | 2021 | 3847 | 0.02 | Why? |
| Vitamin D Deficiency | 1 | 2021 | 1782 | 0.02 | Why? |
| Oxygen | 1 | 2021 | 3715 | 0.02 | Why? |
| Long-Term Care | 1 | 2018 | 2047 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Curriculum | 1 | 2018 | 3083 | 0.02 | Why? |
| Feces | 1 | 2018 | 4235 | 0.02 | Why? |
| Neutrophils | 1 | 2021 | 5476 | 0.02 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Canada | 1 | 2017 | 6018 | 0.02 | Why? |
| Australia | 1 | 2017 | 6306 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.02 | Why? |
| T-Lymphocytes | 1 | 2021 | 6670 | 0.02 | Why? |
| China | 2 | 2020 | 50654 | 0.02 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.01 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.01 | Why? |
| Models, Statistical | 1 | 2018 | 5312 | 0.01 | Why? |
| India | 1 | 2018 | 11875 | 0.01 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Sex Factors | 1 | 2017 | 11014 | 0.01 | Why? |
| Sacroiliac Joint | 1 | 1997 | 26 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.01 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.01 | Why? |
| Arthritis, Infectious | 1 | 1997 | 111 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Osteomyelitis | 1 | 1997 | 131 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Pneumonia, Pneumocystis | 1 | 1996 | 322 | 0.01 | Why? |
| Substance Abuse, Intravenous | 1 | 1996 | 411 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Regression Analysis | 1 | 1996 | 2484 | 0.01 | Why? |
| Liver Cirrhosis | 1 | 1996 | 1810 | 0.00 | Why? |